DelveInsight’s, “Glaucoma Pipeline Insight, 2025,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Glaucoma pipeline landscape. It covers the Glaucoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Glaucoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Glaucoma Pipeline Report to explore emerging therapies, key players, and future treatment landscapes @ Glaucoma Pipeline Outlook Report

Key Takeaways from the Glaucoma Pipeline Report

• In May 2025, Gainesville Eye Associates announced a study of visual field assessments between the TEMPO, VisuALL, and HFA perimeters. Subjects will be assessed at 1 visit. Clinical evaluations will include MD, PSD, FT, VFI, OCT, and a questionnaire.
• DelveInsight’s Glaucoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Glaucoma treatment.
• The leading Glaucoma Companies such as Santen Pharmaceuticals, Visiox Pharma, Nicox Ophthalmics, pH Pharma, Omikron Italia, Tarsier Pharma, TearClear, Laboratoires Thea, EMS, Peregrine Ophthalmic, Betaliq, Inc., Ocuphire Pharma, Inc., HK inno.N, VivaVision Biotech, Qlaris Bio, and others.
• Promising Glaucoma Pipeline Therapies such as EYEOP1, Latanoprost 0.005%, POLAT-001, Ranibizumab, Mitomycin (MMC), PRM-151, Triesence, Timolol, latanoprost, Xalatan, Travatan Z and others.

Discover how the Glaucoma treatment paradigm is evolving. Access DelveInsight’s in-depth Glaucoma Pipeline Analysis for a closer look at promising breakthroughs @ Glaucoma Clinical Trials and Studies

Glaucoma Emerging Drugs Profile

• GmbH NCX 470: Nicox Ophthalmics

NCX 470 is a novel, second-generation nitric oxide (NO)-donating prostaglandin analog that is currently being developed by Nicox Ophthalmics. NCX-470 may assist glaucoma patients by a mechanism other than IOP lowering, notably by enhancing ocular perfusion. IOP reduction is the most common treatment for glaucoma, and preliminary studies suggest that if approved, NCX-470’s dual mechanistic approach (nitric oxide donation and prostaglandin F2 activity) could make it the most effective single-agent glaucoma medicine in terms of IOP-lowering efficacy. Currently, the drug is in Phase III stage of its clinical study for the treatment of open-angle glaucoma or ocular hypertension.

• DE-126: Santen Pharmaceuticals

DE-126 (ONO-9054) is a once-daily prostaglandin eye drop drug product with a novel, dual-mode of action that activates both FP and EP3 receptors (both FP and EP3 receptors are prostaglandin receptors). As it has been reported that both receptors have an effect in reducing intraocular pressure, ONO-9054 is expected to give a new therapeutic options for the treatment of glaucoma. It is likely to show a superior IOP lowering effect compared to FP receptor agonists. Currently, the drug is in Phase III stage of its clinical study for the treatment of open-angle glaucoma or ocular hypertension.

• POLAT 001: Peregrine Ophthalmic

POLAT-001 is a sustained released product of latanoprost for the medical treatment of glaucoma. The drug is a 100 nm-long nanoliposome containing latanoprost. Lipolat is an extended release drug delivery solution that is a ground breaking development in nanomedicine for ophthalmology. Liposomal latanoprost has completed a pilot Phase IIa trial in the US for glaucoma indication.

• BTQ-1902: Betaliq, Inc.

BTQ 1902 is an EyeSol based formulation of timolol, the most commonly prescribed beta blocker. Beta blockers are one of the most commonly prescribed classes of medicines to treat glaucoma. Beta blockers reduce Intraocular Pressure (IOP) by blockade of sympathetic nerve endings in the ciliary epithelium causing a fall in aqueous humour production. Beta blockers are often prescribed in combination with other glaucoma medications. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Open-Angle Glaucoma.

• ST266: Noveome Biotherapeutics

ST266 is a non-cellular biologic drug candidate, currently considered “investigational,” since it is not yet approved by the U.S. Food and Drug Administration (FDA). The clinical trials are designed to examine and confirm that ST266 is safe and effective in humans with the goal of bringing this unique product to potentially millions of patients who suffer from complex diseases and conditions in ophthalmology, neurology, dermatology—and beyond. ST266 is made by the proprietary method of culturing amnion epithelial cells that are harvested from donated full-term placentas normally discarded after birth. It contains hundreds of biologically active proteins and other factors crucial to neuroprotection, the modulation of inflammation, cell recovery and healing. These various proteins and factors are delivered in physiologic concentrations that have been shown, in preclinical and clinical studies to date, to be well-tolerated with demonstrated biologic activity. In preclinical studies, ST266 has been shown to be neuroprotective and to resuscitate damaged and diseased retinal ganglion cells, offering the possibility of a novel treatment for glaucoma. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Glaucoma.

The Gastroparesis Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Gastroparesis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gastroparesis Treatment.
• Gastroparesis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Gastroparesis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gastroparesis market

Explore groundbreaking therapies and clinical trials in the Gastroparesis Pipeline. Access DelveInsight’s detailed report now! @ New Gastroparesis Drugs

Glaucoma Companies

Santen Pharmaceuticals, Visiox Pharma, Nicox Ophthalmics, pH Pharma, Omikron Italia, Tarsier Pharma, TearClear, Laboratoires Thea, EMS, Peregrine Ophthalmic, Betaliq, Inc., Ocuphire Pharma, Inc., HK inno.N, VivaVision Biotech, Qlaris Bio, and others.

Glaucoma Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Glaucoma Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Download DelveInsight’s latest report to gain strategic insights into upcoming therapies and key developments @ Glaucoma Market Drivers and Barriers, and Future Perspectives

Scope of the Glaucoma Pipeline Report

• Coverage- Global
• Glaucoma Companies- Santen Pharmaceuticals, Visiox Pharma, Nicox Ophthalmics, pH Pharma, Omikron Italia, Tarsier Pharma, TearClear, Laboratoires Thea, EMS, Peregrine Ophthalmic, Betaliq, Inc., Ocuphire Pharma, Inc., HK inno.N, VivaVision Biotech, Qlaris Bio, and others.
• Glaucoma Pipeline Therapies- EYEOP1, Latanoprost 0.005%, POLAT-001, Ranibizumab, Mitomycin (MMC), PRM-151, Triesence, Timolol, latanoprost, Xalatan, Travatan Z and others.
• Glaucoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Glaucoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Glaucoma drug development? Find out in DelveInsight’s exclusive Glaucoma Pipeline Report—access it now! @ Glaucoma Emerging Drugs and Major Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Glaucoma Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Glaucoma Disease– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. NCX 470: Nicox Ophthalmics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. POLAT 001: Peregrine Ophthalmic
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ST266: Noveome Biotherapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. RTC-1119: Ripple Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Glaucoma Disease Key Companies
21. Glaucoma Disease Key Products
22. Glaucoma Disease- Unmet Needs
23. Glaucoma Disease- Market Drivers and Barriers
24. Glaucoma Disease- Future Perspectives and Conclusion
25. Glaucoma Disease Analyst Views
26. Glaucoma Disease Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/glaucoma-pipeline-insight